SecBot SecBot
PRESS-RELEASE ·Filed Jun 13, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Key catalysts ahead: Phase 3 initiation details, regulatory interactions, and any partnership interest in the PWS program.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$89.70
T+0 close · Jun 13, 2026 · via day close
Latest settled
+12.66%
T+60 · $101.06
Vs SPY
+11.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $89.70entry
  2. T+1 · 5mo ago +0.02%α +0.62% · $89.72
  3. T+5 · 5mo ago +13.03%α +14.42% · $101.39
  4. T+20 · 4mo ago +19.83%α +20.58% · $107.49
  5. T+60 · 2mo ago +12.66%α +11.66% · $101.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide in Prader-Willi syndrome at ENDO 2026, showing clinically meaningful BMI reductions, fat mass loss with lean mass preservation, and improvements in hyperphagia and anxiety. The results de-risk the path to Phase 3 development in a large unmet-need population, reinforcing the MC4R agonism thesis.

Key Facts

  • Phase 2 trial of setmelanotide in PWS (N=17) showed -3.06% mean BMI reduction at Month 6; 8 of 10 patients with moderate-to-severe hyperphagia achieved ≥7-point HQ-CT improvement.
  • DEXA scans (N=16) showed +0.74% mean lean mass gain and -4.19% mean fat mass loss; 6 of 9 adults had >5% fat mass reduction.
  • 10 of 15 patients with baseline PADQ >11 achieved ≥11-point improvement in anxiousness/distress behaviors.
  • Safety profile consistent with established setmelanotide data; no new safety signals.
  • Company advancing to Phase 3 in PWS, a condition affecting ~400,000 people globally with limited effective treatments.

Financial Impact

No financial data provided in the press release; Phase 2 data de-risks a potential $500M+ peak sales opportunity in PWS (est. 8,500-12,750 US patients with hyperphagia/obesity), but no revenue guidance or deal value disclosed.

revenuepipeline value

Risk Factors

  • Phase 3 trials may fail to replicate these results in a larger, more diverse population.
  • PWS is a complex syndrome; regulatory path for hyperphagia endpoint is not fully established.
  • Competition from other MC4R agonists or alternative therapies could limit commercial uptake.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311380

Track record

26 reports on RYTM

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 13, 2026